Who are Methylnaltrexone (MOA-728)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Methylnaltrexone (MNTX), SC Methylnaltrexone (MNTX).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methylnaltrexone-moa-728.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Methylnaltrexone (MOA-728) — Competitive Intelligence Brief

Methylnaltrexone (MOA-728) (Methylnaltrexone (MOA-728)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Peripheral mu-opioid receptor antagonist. Area: Gastroenterology / Supportive Care.

phase 3 Peripheral mu-opioid receptor antagonist Mu-opioid receptor (peripheral) Gastroenterology / Supportive Care Small molecule Live · refreshed every 30 min

Target snapshot

Methylnaltrexone (MOA-728) (Methylnaltrexone (MOA-728)) — Bausch Health Americas, Inc.. Methylnaltrexone is a peripheral mu-opioid receptor antagonist that blocks opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, thereby reversing opioid-induced constipation while preserving central analgesia.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Methylnaltrexone (MOA-728) TARGET	Methylnaltrexone (MOA-728)	Bausch Health Americas, Inc.	phase 3	Peripheral mu-opioid receptor antagonist	Mu-opioid receptor (peripheral)
Methylnaltrexone (MNTX)	Methylnaltrexone (MNTX)	Bausch Health Americas, Inc.	marketed	Peripheral mu-opioid receptor antagonist	Mu-opioid receptor (peripheral)
SC Methylnaltrexone (MNTX)	SC Methylnaltrexone (MNTX)	Bausch Health Americas, Inc.	phase 3	Peripheral mu-opioid receptor antagonist	Mu-opioid receptor (peripheral)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Peripheral mu-opioid receptor antagonist class)

Bausch Health Americas, Inc. · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methylnaltrexone (MOA-728) — Competitive Intelligence Brief. https://druglandscape.com/ci/methylnaltrexone-moa-728. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab